Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Health outcomes research
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Health outcomes research
Saturday, December 7, 2024, 5:30 PM-7:30 PM
Disclosures: Grosso: Tevogen Bio: Current Employment. Flomenberg: Tevogen Bio: Current Employment. Gergis: Iovance: Current equity holder in publicly-traded company; VOR: Consultancy; Moderna: Current equity holder in publicly-traded company; Biontech: Current equity holder in publicly-traded company; Kite: Other: Travel Support, Speakers Bureau; Incyte: Other: Travel Support, Speakers Bureau; Astellas: Other: Travel Support, Speakers Bureau; Jazz: Other: Travel Support, Speakers Bureau; Autolus: Consultancy.